Raloxifene - Study

Phase 3Small molecule

HHan Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair

Raloxifene - Study is one of 11 small molecule programs targeting CLE. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CLEActive, not recruiting

CLEPhase 3

Active, not recruiting

Competition

Competitive Landscape

14 competitors in CLE

#DrugCompanyPhaseTrials

Zytiga

Johnson & Johnson

Phase 3

1 2

Zuragard

ZZurex Pharma, Inc.

Phase 2

1 3

Raloxifene - Study

HHan Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair

Phase 3

1 4

Keto Acid

UUniversity Hospital, Clermont-Ferrand

Phase 3

1 5

Brethine

Sanofi

Preclinical

2 6

ATR-258

AAtrogi AB

Phase 2

1 7

Povidine-Iodine

MMidAtlantic Retina

Phase 2

1 8

Pharmacokinetics

Pfizer

Phase 1

1 9

Clenbuterol

UUniversity of Copenhagen

Preclinical

1 10

Triptorelin Acetate

Ipsen

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2/3Active, not recruiting

CLE

NCT06062810

Clinical

Trials by Indication[1]

CLE1 trial

Pharmacogenomics ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms

Active, not recruiting·HHan Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair·Phase 2/3·NCT06062810·600 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Raloxifene - Study. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Raloxifene - Study compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Raloxifene - Study. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: HHan Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair

Raloxifene - Study

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

CLE1 trial

References

Drug Info

Quick Facts

Related News